Jamie David Knight

Title: Jamie David Knight: Innovator in Potassium Channel Inhibitors

Introduction

Jamie David Knight is a notable inventor based in Middlesex, GB. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of potassium channel inhibitors. His innovative work has the potential to impact various medical conditions.

Latest Patents

Jamie David Knight holds a patent for thieno[3,2-c]pyridine potassium channel inhibitors. This invention provides thienopyridine compounds that act as potassium channel inhibitors. Additionally, it includes pharmaceutical compositions comprising thienopyridines. The methods outlined in the patent focus on using thienopyridines for the treatment or prevention of cancer, arrhythmias, autoimmune diseases, and inflammatory diseases. These conditions include gastric cancer, atrial fibrillation, type-2 diabetes mellitus, rheumatoid arthritis, type-1 diabetes, inflammatory bowel disorder, and demyelinating disorders such as multiple sclerosis. He has 1 patent to his name.

Career Highlights

Jamie David Knight is associated with Xention Limited, where he continues to advance his research and development efforts. His work at the company emphasizes the importance of innovative solutions in the pharmaceutical industry.

Collaborations

Some of his coworkers include John Ford and Helen Jane Payne, who contribute to the collaborative environment at Xention Limited.

Conclusion

Jamie David Knight's contributions to the field of potassium channel inhibitors highlight his role as an innovator in pharmaceutical sciences. His work has the potential to lead to significant advancements in the treatment of various medical conditions.